^(89)SrCl_2联合唑来膦酸治疗前列腺癌骨转移

Combined therapy of ^(89)Sr-chloride and zoledronic acid in prostate cancer patients with bone metastases

目的探讨89SrCl2联合唑来膦酸与单用89SrCl2对前列腺癌骨转移癌的治疗效果及副作用。方法 59例前列腺癌并骨转移患者分为两组,A组单独应用89SrCl2治疗骨转移灶,B组联合应用89SrCl2和唑来膦酸治疗,连续观察6个月,对两组患者的疗效进行对比分析。结果在控制前列腺癌骨转移方面,A组有效率为75.6%,B组有效率为90.9%。两组间差异有统计学意义。结论联合应用89SrCl2和唑来膦酸可明显提高前列腺癌骨转移病灶治疗的有效率。

Objective The aim of this study was to 6ompare the efficacy of treatment with 89Sr：chloride separately vs. 89Sr-ebloride treatment combined with Zoledronic acid in prostate cancer patients with bone metastases. Methods We analyzed fifty nine metastatic prostate cancer patients aged between 53 and 84 years, who we divided into two treatment groups： 37 pts re- ceived Sr-89 monotherapy （ group A） ; 22 patients received Sr-89 combined with Zoledronic acid （ group B ） ; Follow-up was 6 months. Results The response rate was 75. 6% of patients in group A and 90. 9% of patients in group B. There was significmat difference between two groups. Conclusion Our findings indicate that combined therapy of SgSr-chloride and zoledronic acid in prostate cancer patients with bone metastases is more effective in treating pain and improving clinical conditions than 89Sr-chloride used separately.